At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
ACZ885drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multicenter, Efficacy and Safety Study of 4-month Canakinumab Treatment With 6-month Follow-up in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).
In Brief
A Phase 2 clinical trial evaluating ACZ885 for TNF-receptor Associated Periodic Syndromes (TRAPS). Completed, enrolled 20 participants across 6 sites in 3 countries.
Detailed Summary
This trial will assess the safety and efficacy of ACZ885 in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIreland, Italy, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2010
First PostedNov 2010
Primary CompletionJun 2014
TodayJul 2026
First PostedNov 17, 2010
Enrollment StartOct 1, 2010
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 15.6 years ago
Interventions
ACZ885drug